ServiceNow CEO Bill McDermott says his firm is at the forefront of a shift from artificial intelligence “fascination” to companies making AI-led business strategies.
Vas Narasimhan, CEO of Novartis, comments on the progress of the firm’s Kisqali metastatic breast cancer drug after the company recently received an extended approval for it from the U.S. Food and Drug Administration.
Gero Jung, chief economist at Mirabaud Asset Management, weighs in on the Federal Reserve’s upcoming interest rate decision, saying a 25 basis point rate cut appears most likely.